ATE439378T1 - Verfahren zur identifizierung von indirekten igf- 1-agonisten - Google Patents

Verfahren zur identifizierung von indirekten igf- 1-agonisten

Info

Publication number
ATE439378T1
ATE439378T1 AT06026832T AT06026832T ATE439378T1 AT E439378 T1 ATE439378 T1 AT E439378T1 AT 06026832 T AT06026832 T AT 06026832T AT 06026832 T AT06026832 T AT 06026832T AT E439378 T1 ATE439378 T1 AT E439378T1
Authority
AT
Austria
Prior art keywords
igf
agonists
identifying
identifying indirect
relates
Prior art date
Application number
AT06026832T
Other languages
English (en)
Inventor
Michelle Schaffer
Mark Ultsch
Felix Vajdos
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE439378T1 publication Critical patent/ATE439378T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
AT06026832T 2001-02-09 2002-02-01 Verfahren zur identifizierung von indirekten igf- 1-agonisten ATE439378T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26797701P 2001-02-09 2001-02-09
US28707201P 2001-04-27 2001-04-27

Publications (1)

Publication Number Publication Date
ATE439378T1 true ATE439378T1 (de) 2009-08-15

Family

ID=26952796

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06026832T ATE439378T1 (de) 2001-02-09 2002-02-01 Verfahren zur identifizierung von indirekten igf- 1-agonisten
AT02724908T ATE349469T1 (de) 2001-02-09 2002-02-01 Kristallisierung von igf-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02724908T ATE349469T1 (de) 2001-02-09 2002-02-01 Kristallisierung von igf-1

Country Status (19)

Country Link
US (8) US7084240B2 (de)
EP (3) EP1801120A1 (de)
JP (2) JP4489352B2 (de)
KR (1) KR100872613B1 (de)
CN (1) CN100439397C (de)
AT (2) ATE439378T1 (de)
AU (1) AU2002255508B2 (de)
BR (1) BR0207422A (de)
CA (1) CA2431033A1 (de)
DE (3) DE60217066D1 (de)
DK (2) DK1358209T3 (de)
ES (2) ES2331150T3 (de)
HU (1) HUP0500733A3 (de)
IL (2) IL156435A0 (de)
MX (1) MXPA03007042A (de)
NZ (3) NZ548358A (de)
PL (1) PL374181A1 (de)
WO (1) WO2002064627A2 (de)
ZA (1) ZA200304900B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7071300B2 (en) * 2001-03-14 2006-07-04 Genentech, Inc. IGF antagonist peptides
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
JP4344242B2 (ja) * 2001-09-18 2009-10-14 バイオエキスパータイズ， エルエルシー Ｉｇｆ結合タンパク質由来のペプチドまたは低分子
US6914049B2 (en) * 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US20070219767A1 (en) * 2003-05-06 2007-09-20 Carter Daniel C Atomic coordinates of albumin drug complexes and method of use of pharmaceutical development
EP1684705A4 (de) * 2003-11-03 2008-02-20 New Century Pharmaceuticals Albumin-bindungsstellen zur beurteilung von arzneimittelwechselwirkungen und verfahren zur beurteilung oder zum entwurf von arzneimitteln auf basis ihrer albuminbindungseigenschaften
EA010885B1 (ru) 2003-12-08 2008-12-30 Бентли Фармасьютикалз, Инк. Фармацевтические композиции и способы лечения инсулином
WO2005108424A1 (en) * 2004-05-06 2005-11-17 Genentech, Inc. Crystal structure of the complex of hepatocyte growth factor bata chain with met receptor and methods of use
US20060003931A1 (en) * 2004-05-06 2006-01-05 Genentech, Inc. Crystal structure of the hepatocyte growth factor and methods of use
MX2007000883A (es) 2004-07-19 2007-04-02 Biocon Ltd Conjugados de insulina-oligomero, formulaciones y usos de los mismos.
EP1848812A4 (de) * 2004-10-01 2011-11-09 Life Technologies Corp Zufuhrpuffer, systeme und verfahren zur in-vitro-synthese von biomolekülen
US7556776B2 (en) * 2005-09-08 2009-07-07 President And Fellows Of Harvard College Microfluidic manipulation of fluids and reactions
BRPI0812768A2 (pt) * 2007-06-08 2014-12-02 Massachusetts Inst Technology Igf para o tratamento de síndrome de rett e transtornos sinápticos.
US8350007B2 (en) 2007-08-17 2013-01-08 The Regents Of The University Of California Crystal structure of human mitoNEET protein
CN101139391B (zh) * 2007-08-21 2012-07-25 陈志南 Cd147胞外区晶体结构及应用
US9664619B2 (en) * 2008-04-28 2017-05-30 President And Fellows Of Harvard College Microfluidic device for storage and well-defined arrangement of droplets
BR112012001363A2 (pt) 2009-07-22 2016-11-08 Ipsen Pharma Sas análogo de igf-1, composição farmacêutica,e, método para tratar condições ou doenças mediadas pela ligação do receptor de igf-1
WO2011011071A2 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
WO2011047204A1 (en) * 2009-10-14 2011-04-21 Mount Sinai School Of Medicine Method of treating memory disorders and enhancing memory using igf-ii compounds
EP2830625A1 (de) * 2012-03-28 2015-02-04 Merck Sharp & Dohme Corporation Hemmer des insulinähnlichen wachstumsfaktor-1-rezeptors
KR101711584B1 (ko) * 2012-12-18 2017-03-02 재단법인 의약바이오컨버젼스연구단 변형된 eprs 단백질의 결정 구조 및 이의 결정화 방법
KR102313381B1 (ko) 2013-12-19 2021-10-14 퓨어테인 바이오사이언스, 엘엘씨. 동물을 치료하기 위한 방법
JP2022547948A (ja) 2019-09-09 2022-11-16 ザ・ユニバーシティ・オブ・シカゴ 片頭痛の処置のための併用療法
WO2021248160A1 (en) * 2020-06-01 2021-12-09 Loma Linda University Health Methods of treatment of a cytokine storm

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US589867A (en) * 1897-09-14 Clothes-line hanger
US577276A (en) * 1897-02-16 Quarter-saver iv
US4672108A (en) 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
DE3327709A1 (de) 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
JPH0720993B2 (ja) 1985-08-22 1995-03-08 グロペップ プロプライエタリー リミテッド 生長因子
DE3717370A1 (de) 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
US4833233A (en) 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
WO1989005822A1 (en) 1987-12-24 1989-06-29 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
US5470828A (en) 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
ATE86496T1 (de) 1988-02-05 1993-03-15 Ciba Geigy Ag Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten.
US4988675A (en) 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
US5093317A (en) 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
GB8920381D0 (en) 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5028224A (en) * 1990-01-09 1991-07-02 Kimberly-Clark Corporation Apparatus for intermittently depositing particulate material in a substrate
US5374620A (en) 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
SE9100099D0 (sv) 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5187151A (en) 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5202119A (en) 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
EP0597033B1 (de) 1991-08-01 1997-04-09 Genentech, Inc. IGF-I zur Verbesserung der neuronale Lage
US5126314A (en) * 1991-09-06 1992-06-30 Eastman Kodak Company Mixture of dyes for black dye donor for thermal color proofing
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
JPH07508025A (ja) 1992-05-08 1995-09-07 トーマス・ジェファーソン・ユニバーシティ インスリン様増殖因子（ｉｇｆ−１）類似体
SE9201573D0 (sv) 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
WO1993025687A1 (en) 1992-06-09 1993-12-23 Chiron Corporation Crystallization of m-csf
JP3623502B2 (ja) 1992-06-12 2005-02-23 セファロン，インコーポレイテッド 末梢神経障害の予防および治療
NZ255461A (en) 1992-08-20 1996-12-20 Biotechnology & Biolog Science Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity
US5273961A (en) 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
CA2132871A1 (en) 1993-01-25 1994-08-04 Alan C. Moses Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties
DK72793D0 (da) 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5534488A (en) 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
US5407810A (en) 1993-08-20 1995-04-18 Genentech, Inc. Aqueous multiple-phase isolation of polypeptide
US5504188A (en) 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5597893A (en) 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
YU18596A (sh) 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
SE9501472D0 (sv) 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
ES2202455T3 (es) 1995-06-22 2004-04-01 Biogen, Inc. Cristales de fragmentos del ligando cd40 y su uso.
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
JP3417230B2 (ja) * 1996-09-25 2003-06-16 信越化学工業株式会社 型取り母型用光硬化性液状シリコーンゴム組成物
US5898067A (en) 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
US5898028A (en) 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
CA2294833A1 (en) 1997-07-03 1999-01-14 Smithkline Beecham Corporation Crystal structures of anti-factor ix fab fragments and methods of use for peptidomimetic design
US5876242A (en) * 1997-07-21 1999-03-02 Williams; Hugh D. Remote battery extension apparatus
NZ506091A (en) 1998-01-21 2003-07-25 Brigham & Womens Hospital Circulating insulin-like growth factor-i and prostate cancer risk
WO2000023469A2 (en) 1998-10-16 2000-04-27 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
JP2004512010A (ja) 2000-03-29 2004-04-22 ディージーアイ・バイオテクノロジーズ・エル・エル・シー インスリン及びｉｇｆ−１受容体のアゴニスト及びアンタゴニスト
EP1399475A2 (de) 2001-06-07 2004-03-24 F. Hoffmann-La Roche Ag Mutanten igf-bindender proteine und verfahren zur produktion deren antagonisten
US20040137518A1 (en) * 2002-01-31 2004-07-15 Lambert Millard Hurst CRYSTALLIZED PPARa LIGAND BINDING DOMAIN POLYPEPTIDE AND SCREENING METHODS EMPLOYING SAME
JP3680801B2 (ja) * 2002-02-27 2005-08-10 株式会社デンソー 回転電機の巻線接合方法

Also Published As

Publication number Publication date
ES2331150T3 (es) 2009-12-22
US20050215477A1 (en) 2005-09-29
ES2278020T3 (es) 2007-08-01
BR0207422A (pt) 2005-04-19
EP1772464A3 (de) 2007-10-03
DE60233359D1 (de) 2009-09-24
US20060287235A1 (en) 2006-12-21
DE60217066T2 (de) 2007-07-12
EP1801120A1 (de) 2007-06-27
EP1772464A2 (de) 2007-04-11
ATE349469T1 (de) 2007-01-15
IL156435A (en) 2009-09-22
NZ548359A (en) 2007-11-30
MXPA03007042A (es) 2004-05-24
US7084240B2 (en) 2006-08-01
CN100439397C (zh) 2008-12-03
PL374181A1 (en) 2005-10-03
US20060276397A1 (en) 2006-12-07
US20060270839A1 (en) 2006-11-30
WO2002064627A3 (en) 2003-07-31
DE60217066D1 (de) 2007-02-08
DK1772464T3 (da) 2009-12-14
US20060293507A1 (en) 2006-12-28
JP2009215299A (ja) 2009-09-24
EP1358209B1 (de) 2006-12-27
DK1358209T3 (da) 2007-05-07
WO2002064627A2 (en) 2002-08-22
ZA200304900B (en) 2005-07-27
US7433788B2 (en) 2008-10-07
US20060281905A1 (en) 2006-12-14
KR20040064610A (ko) 2004-07-19
HUP0500733A2 (hu) 2005-10-28
KR100872613B1 (ko) 2008-12-09
NZ526672A (en) 2006-10-27
US7238658B2 (en) 2007-07-03
US7354769B2 (en) 2008-04-08
US7297763B2 (en) 2007-11-20
JP4489352B2 (ja) 2010-06-23
CA2431033A1 (en) 2002-08-22
HK1060138A1 (en) 2004-07-30
IL156435A0 (en) 2004-01-04
EP1358209A2 (de) 2003-11-05
US20020165155A1 (en) 2002-11-07
NZ548358A (en) 2008-04-30
US7596455B2 (en) 2009-09-29
JP2005503329A (ja) 2005-02-03
CN1703425A (zh) 2005-11-30
EP1772464B1 (de) 2009-08-12
DE60217066T4 (de) 2010-07-01
HUP0500733A3 (en) 2010-01-28
US20060287510A1 (en) 2006-12-21
AU2002255508B2 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
ATE439378T1 (de) Verfahren zur identifizierung von indirekten igf- 1-agonisten
ATE343591T1 (de) Antagonist für die multimerisierung von hiv-1 vif-protein
DK1316801T3 (da) Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer
DE60216245D1 (de) Funktionelles oberflächendisplay von polypeptiden
DE50003766D1 (de) Verfahren und vorrichtung zum nachweis und zur quantifizierung von biomolekülen
DE602004019812D1 (de) Marker für neuromyelitis optica
EP1589106A4 (de) Adiponektin-rezeptor und dafür kodierendes gen
ATE382148T1 (de) Antikörper für apoptosemarker und anwendungsverfahren
ATE539425T1 (de) Bereitstellung von verkehrsinformationen mit unterverknüpfungen von verknüpfungen
ATE333522T1 (de) Verfahren zur bestimmung von mehrere analyten
WO2008060483A3 (en) Protein-protein interaction biosensors and methods of use thereof
WO2002086081A3 (en) Methods and systems for identifying proteins
BR0208479B1 (pt) composiÇço e mÉtodo para inibir oxidaÇço em estoques bÁsicos de grupo i de api com teor elevado de enxofre.
DE60207016D1 (de) Verfahren und Kit zur Quantifizierung von Beta-Laktam Penizillinen
NO20052553D0 (no) Cobalaminanalyse.
WO2005103713A3 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
WO2004070389A8 (en) Assay for protein isoforms
DE60325640D1 (de) Verfahren zur identifizierung von transmembranrezeptoragonisten mit reduzierter internalisierung
WO2025101639A3 (en) Methods for detection of post-translational modifications
BR0215452A (pt) Teste de proteìna tirosina-fosfatase (ptpase) altamente sensitivo com o emprego de 6,8-diflúor-4-metil-umbeliferilfosfato
DE60040010D1 (de) Ein Verfahren zum Auffinden vom Prostatakrebs
BRPI0413610A (pt) método para a identificação de agonistas ou inibidores da proteìna quinase irs
ATE368126T1 (de) Verfahren zur identifizierung von protein sic inhibitoren
WO2004010108A3 (en) Method for the identification of ligands
DE10293635D2 (de) Träger für immobilisierte Biomoleküle und Verfahren zur Immobilisierung von Biomolekülen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1772464

Country of ref document: EP